| Literature DB >> 27010810 |
Bénédicte Daydé-Cazals1, Bénédicte Fauvel1, Mathilde Singer1, Clémence Feneyrolles1, Benoit Bestgen1, Fanny Gassiot1, Aurélia Spenlinhauer1, Pierre Warnault1, Nathalie Van Hijfte1, Nozha Borjini1, Gwénaël Chevé1, Abdelaziz Yasri1.
Abstract
Efforts were made to improve a series of potent dual ABL/SRC inhibitors based on a 7-azaindole core with the aim of developing compounds that demonstrate a wider activity on selected oncogenic kinases. Multi-targeted kinase inhibitors (MTKIs) were then derived, focusing on kinases involved in both angiogenesis and tumorigenesis processes. Antiproliferative activity studies using different cellular models led to the discovery of a lead candidate (6z) that combined both antiangiogenic and antitumoral effects. The activity of 6z was assessed against a panel of kinases and cell lines including solid cancers and leukemia cell models to explore its potential therapeutic applications. With its potency and selectivity for oncogenic kinases, 6z was revealed to be a focused MTKI that should have a bright future in fighting a wide range of cancers.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27010810 DOI: 10.1021/acs.jmedchem.6b00087
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446